Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$12.03
-4.60% on the day
Market cap
$341.9M
Small cap
Revenue · 2025
$82.0M
-46.1% on 2024
Net income · 2025
-$65.8M
-80.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ARCT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2013 |
| SEC CIK | 0001768224 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $82.0M |
| Net income | -$65.8M |
| Operating income | -$76.3M |
| Net margin | -80.2% |
| Operating margin | -93.0% |
| Revenue growth | -46.1% |
| Cash | $230.9M |
| Total assets | $271.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-12-30 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 413 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.5% |
| 1 month | -29.5% |
| 3 months | +80.7% |
| Year to date | +82.2% |
| 1 year | -42.4% |
| From 52-week high | -51.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals Inc. | $11.52 | -6.34% | $335.5M |
| IRD | Opus Genetics Inc. | $4.24 | -8.62% | $352.8M |
| EBS | Emergent BioSolutions Inc. | $6.91 | -1.00% | $354.3M |
| RLMD | Relmada Therapeutics Inc. | $3.36 | -4.27% | $358.4M |
| INDP | Indaptus Therapeutics Inc. | $2.39 | -2.05% | $318.4M |
| CTNM | Contineum Therapeutics Inc. | $8.42 | -1.69% | $316.8M |
| TTRX | Turn Therapeutics Inc. | $10.60 | -4.59% | $315.8M |
| GALT | Galectin Therapeutics Inc. | $3.69 | -4.65% | $372.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier